Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 4/2003

01-04-2003 | Original Article

Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells

Authors: Øystein Bruserud, Elling Ulvestad

Published in: Cancer Immunology, Immunotherapy | Issue 4/2003

Login to get access

Abstract

The ability of acute lymphoblastic leukemia (ALL) blasts to mediate costimulatory signals during T-lymphocyte activation was investigated in an experimental model in which monoclonal T-cell populations were stimulated with standardized activation signals (anti-CD3 and anti-CD28 monoclonal antibodies; phytohemagglutinin, PHA). Leukemia cells from 12 consecutive ALL patients with high peripheral blood blast counts were studied. Proliferative T-cell responses were detected for a majority of these patients when irradiated leukemia blasts were used as accessory cells during activation. T-cell cytokine release was also observed for most patients when using nonirradiated ALL accessory cells. Low or undetectable cytokine levels were usually observed for CD8+ clones, whereas the CD4+ clones often showed a broad cytokine response with release of interleukin-2 (IL-2), IL-4, IL-10, IL-13 and interferon γ(IFN-γ) in the presence of the ALL accessory cells. ALL blasts were also able to function as allostimulatory cells for normal peripheral blood mononuclear responder cells. However, both T-cell proliferation and cytokine release showed a wide variation between ALL patients. The accessory cell function of ALL blasts showed no correlation with the release of immunomodulatory mediators (IL-2, IL-10, IL-15) or the expression of any single adhesion/costimulatory membrane molecule (CD54, CD58, CD80, CD86) by the blasts. We conclude that for a majority of patients, native ALL blasts can mediate costimulatory signals needed for accessory cell-dependent T-cell activation, but differences in costimulatory capacity between ALL patients affects both the proliferative responsiveness and cytokine release by activated T cells.
Literature
1.
2.
go back to reference Bruserud Ø (1998) Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic cells. Cancer Immunol Immunother 46:221CrossRefPubMed Bruserud Ø (1998) Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic cells. Cancer Immunol Immunother 46:221CrossRefPubMed
3.
go back to reference Bruserud Ø (1999) Acute myelogenous leukaemia blasts as accessory cells during T lymphocyte activation; possible implications for future therapeutic strategies. Leukemia 13:1175CrossRefPubMed Bruserud Ø (1999) Acute myelogenous leukaemia blasts as accessory cells during T lymphocyte activation; possible implications for future therapeutic strategies. Leukemia 13:1175CrossRefPubMed
4.
go back to reference Bruserud Ø, Moen T (1984) Production of Interleukin 2-containing growth medium for cloning of human T lymphocytes. J Immunol Methods 71:175CrossRefPubMed Bruserud Ø, Moen T (1984) Production of Interleukin 2-containing growth medium for cloning of human T lymphocytes. J Immunol Methods 71:175CrossRefPubMed
5.
go back to reference Bruserud Ø, Ulvestad E (1999) Effects of γ-irradiation on acute myelogenous leukaemia blasts; in vitro studies of proliferation, constitutive cytokine secretion and accessory cell function during T cell activation. J Hematother Stem Cell Res 8:431CrossRefPubMed Bruserud Ø, Ulvestad E (1999) Effects of γ-irradiation on acute myelogenous leukaemia blasts; in vitro studies of proliferation, constitutive cytokine secretion and accessory cell function during T cell activation. J Hematother Stem Cell Res 8:431CrossRefPubMed
6.
go back to reference Bruserud Ø, Giertsen BT, Ulvestad E (2000) Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immunol 206:36CrossRefPubMed Bruserud Ø, Giertsen BT, Ulvestad E (2000) Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immunol 206:36CrossRefPubMed
7.
go back to reference Bruserud Ø, Ulvestad E (2002) Expression of Fcε-receptors by human acute myelogenous leukemia (AML) blasts; studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics. Leuk Res 26:515CrossRefPubMed Bruserud Ø, Ulvestad E (2002) Expression of Fcε-receptors by human acute myelogenous leukemia (AML) blasts; studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics. Leuk Res 26:515CrossRefPubMed
8.
go back to reference Bruserud Ø, Wendelbo Ø (2001) Biological treatment in acute myelogenous leukemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Exp Opin Biol Ther 1:1005 Bruserud Ø, Wendelbo Ø (2001) Biological treatment in acute myelogenous leukemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Exp Opin Biol Ther 1:1005
9.
go back to reference Bruserud Ø, Hamann W, Patel S, Ehninger G, Pawelec G (1992) IL-2- and IL-4-dependent proliferation of T cell clones derived early after allogeneic bone marrow transplantation: studies of patients with chronic myelogenous leukaemia. Eur J Haematol 48:221PubMed Bruserud Ø, Hamann W, Patel S, Ehninger G, Pawelec G (1992) IL-2- and IL-4-dependent proliferation of T cell clones derived early after allogeneic bone marrow transplantation: studies of patients with chronic myelogenous leukaemia. Eur J Haematol 48:221PubMed
10.
go back to reference Bruserud Ø, Gjertsen BT, Brustugun OT, Bassøe CF, Nesthus I, Akselsen PE, Bühring H-J, Pawelec G (1995) Effects of Interleukin 10 on blast cells derived from patients with acute myelogenous leukaemia. Leukemia 9:1910PubMed Bruserud Ø, Gjertsen BT, Brustugun OT, Bassøe CF, Nesthus I, Akselsen PE, Bühring H-J, Pawelec G (1995) Effects of Interleukin 10 on blast cells derived from patients with acute myelogenous leukaemia. Leukemia 9:1910PubMed
11.
go back to reference Bruserud Ø, Mentzoni L, Foss B, Bergheim J, Berentsen S, Nesthus I (1996) Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of allostimulated interferon-gamma secretion. Cancer Immunol Immunother 43:275CrossRefPubMed Bruserud Ø, Mentzoni L, Foss B, Bergheim J, Berentsen S, Nesthus I (1996) Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of allostimulated interferon-gamma secretion. Cancer Immunol Immunother 43:275CrossRefPubMed
12.
go back to reference Bruserud Ø, Ulvestad E, Berentsen S, Bergheim J, Nesthus I (1998) T lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T cell proliferation. Scand J Immunol 47:54CrossRefPubMed Bruserud Ø, Ulvestad E, Berentsen S, Bergheim J, Nesthus I (1998) T lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T cell proliferation. Scand J Immunol 47:54CrossRefPubMed
13.
go back to reference Bruserud Ø, Gjertsen BT, Foss B, Huang T-S (2001) New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cells—the present use in experimental studies and the possible importance for future therapeutic strategies. Stem Cells 19:1PubMed Bruserud Ø, Gjertsen BT, Foss B, Huang T-S (2001) New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cells—the present use in experimental studies and the possible importance for future therapeutic strategies. Stem Cells 19:1PubMed
14.
go back to reference Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billett A, Sallan SE, Gribben JG, Nadler LM (1996) Pre-B acute lymphoblastic leukemia cells may induce T cell anergy. Blood 88:41PubMed Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billett A, Sallan SE, Gribben JG, Nadler LM (1996) Pre-B acute lymphoblastic leukemia cells may induce T cell anergy. Blood 88:41PubMed
15.
go back to reference Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM (1997) Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90:549PubMed Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM (1997) Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90:549PubMed
16.
go back to reference Cortes JE, Kantarjian H, Freireich EJ (1996) Acute lymphoblastic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat Res 84:291PubMed Cortes JE, Kantarjian H, Freireich EJ (1996) Acute lymphoblastic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat Res 84:291PubMed
17.
go back to reference Costello RT, Mallet F, Chambost H, Sainty D, Gastaut JA, Olive D (1999) Differential modulation of immune recognition molecules by interleukin 7 in human acute leukaemias. Eur Cytokine Netw 10:87PubMed Costello RT, Mallet F, Chambost H, Sainty D, Gastaut JA, Olive D (1999) Differential modulation of immune recognition molecules by interleukin 7 in human acute leukaemias. Eur Cytokine Netw 10:87PubMed
18.
go back to reference Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91:3995PubMed Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91:3995PubMed
19.
go back to reference Gribben JG, Cardoso AA, Schultze JL, Nadler LM (1997) Biologic response modifiers in acute lymphoblastic leukemia. Leukemia 11 [Suppl 4]:S31 Gribben JG, Cardoso AA, Schultze JL, Nadler LM (1997) Biologic response modifiers in acute lymphoblastic leukemia. Leukemia 11 [Suppl 4]:S31
20.
go back to reference Hoelzer D, Gokbuget N (2000) Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 36:49CrossRefPubMed Hoelzer D, Gokbuget N (2000) Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 36:49CrossRefPubMed
21.
go back to reference Kasai M, Akatsuka Y, Emi N, Taji H, Kohno A, Abe A, Tanimoto M, Kodera Y, Saito H (1999) Immune response of posttransplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. Int J Hematol 69:112PubMed Kasai M, Akatsuka Y, Emi N, Taji H, Kohno A, Abe A, Tanimoto M, Kodera Y, Saito H (1999) Immune response of posttransplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. Int J Hematol 69:112PubMed
22.
go back to reference Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G, Bornhauser M (2000) Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 18:139PubMed Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G, Bornhauser M (2000) Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 18:139PubMed
23.
go back to reference Murphy LL, Mazanet MM, Taylor AC, Mestas J, Hughes CC (1999) Single-cell analysis of costimulation by B cells, endothelial cells, and fibroblasts demonstrates heterogeneity in responses of CD4+ memory T cells. Cell Immunol 194:150CrossRefPubMed Murphy LL, Mazanet MM, Taylor AC, Mestas J, Hughes CC (1999) Single-cell analysis of costimulation by B cells, endothelial cells, and fibroblasts demonstrates heterogeneity in responses of CD4+ memory T cells. Cell Immunol 194:150CrossRefPubMed
24.
go back to reference O'Flynn K, Russul-Saib M, Ando I, Wallace DL, Beverley PCL, Boylston AW, Linch DC (1986) Different pathways of human T cell activation revealed by PHA-P and PHA-M. Immunology 57:55PubMed O'Flynn K, Russul-Saib M, Ando I, Wallace DL, Beverley PCL, Boylston AW, Linch DC (1986) Different pathways of human T cell activation revealed by PHA-P and PHA-M. Immunology 57:55PubMed
25.
go back to reference Pawelec G (1994) Immune surveillance in leukaemia: rationale for immunotherapy? Hematol Rev 8:123 Pawelec G (1994) Immune surveillance in leukaemia: rationale for immunotherapy? Hematol Rev 8:123
26.
go back to reference Pawelec G, Max H, Halder T, Bruserud Ø, Merl A, da Silva P, Kalbacher H (1996) BCR/ABL leukemia oncogen fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118PubMed Pawelec G, Max H, Halder T, Bruserud Ø, Merl A, da Silva P, Kalbacher H (1996) BCR/ABL leukemia oncogen fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118PubMed
27.
go back to reference Shores EW, Love PE (1997) TCRξ chain in T cell development and selection. Curr Opin Immunol 9:380PubMed Shores EW, Love PE (1997) TCRξ chain in T cell development and selection. Curr Opin Immunol 9:380PubMed
28.
go back to reference van Lier RAW, Boot JHA, Verhoeven AJ, de Groot ER, Brouwer M, Aarden LA (1987) Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell independent induction of interleukin 2 responsiveness in T cells by ε-anti-CD3. J Immunol 139:2873PubMed van Lier RAW, Boot JHA, Verhoeven AJ, de Groot ER, Brouwer M, Aarden LA (1987) Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell independent induction of interleukin 2 responsiveness in T cells by ε-anti-CD3. J Immunol 139:2873PubMed
29.
go back to reference Whiteside TL, Rabinowich H (1998) The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46:175PubMed Whiteside TL, Rabinowich H (1998) The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46:175PubMed
Metadata
Title
Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells
Authors
Øystein Bruserud
Elling Ulvestad
Publication date
01-04-2003
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 4/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0364-5

Other articles of this Issue 4/2003

Cancer Immunology, Immunotherapy 4/2003 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine